Big Pharma Licensing Trends, 2011-15
|出版日期||內容資訊||英文 88 Pages
Key to predicting future trends in Big Pharma deal-making is reviewing the peer set's most recent activity. Between 2011 and 2015, Big Pharma - a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more - signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%. Overall, Big Pharma represented the majority of the monetary value of all biopharma partnerships: the peer group was responsible for $133bn of deal-making during the five-year period versus the $254bn in all comparable biopharma alliances (including the Big Pharma peer set).
As of mid-2015, Big Pharma companies had in the pipeline for cancer approximately 279 candidates, which is well over two times that of any other therapeutic area. This was reflected in deal-making; between 2011 and 2015, nearly two-thirds of Big Pharma's in- and out-licensing deals were in oncology, and immuno-oncology was the key driver of oncology in-licensing.
This report addresses the following questions: